SCHEMBL3579416

SCHEMBL3579416

COC(=O)C1CCC(OCCO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ SMYD2 Q9NRG4 3/20 0.36
▸ IDO1 P14902 1/20 0.36
▸ ELANE P08246 1/20 0.36
▸ LTA4H P09960 1/20 0.35
▸ GAA P10253 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ CD38 P28907 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10437825 0.83 ALDH1A1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL18603624 0.83 ALDH1A1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL10437826 0.83 ALDH1A1 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL30192997 0.82 ALDH1A1 (0.40) NPC1RAB9ASMN1; SMN2CYP3A4HTT
SCHEMBL27015413 0.82 ALDH1A1 (0.40) NPC1RAB9ASMN1; SMN2CYP3A4HTT
SCHEMBL3580266 0.81 SMYD2 (0.36) SMN1; SMN2CYP3A4HTTMAPTSMYD2
SCHEMBL29487501 0.80 CTSC (0.37) SMN1; SMN2CYP3A4HTTALDH1A1HPGD
SCHEMBL3577005 0.80 SMYD2 (0.40) SMN1; SMN2CYP3A4HTTSMYD2
SCHEMBL26964739 0.79 ALDH1A1 (0.39) NPC1RAB9ASMN1; SMN2HTTALDH1A1
SCHEMBL26964685 0.78 ALDH1A1 (0.38) NPC1RAB9ASMN1; SMN2CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304412-B2 Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-11-06 — — US disclosed
US-8304412-B2 Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-11-06 — — US disclosed
US-20100022544-A1 CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-01-28 — — US disclosed
US-20100022544-A1 CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022544-A1 CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF QDPR, TPMT, PTGIS NPC1 1441/4885RAB9A 3484/4885SMN1; SMN2 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback